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Abstract
Background: Adverse health effects of tobacco smoke arise partly from its influence on innate and adaptive
immune responses, leading to impaired innate immunity and host defense. The impact of smoking on allergic
asthma remains unclear, with various reports demonstrating that cigarette smoke enhances asthma development
but can also suppress allergic airway inflammation. Based on our previous findings that immunosuppressive effects
of smoking may be largely attributed to one of its main reactive electrophiles, acrolein, we explored the impact of
acrolein exposure in a mouse model of ovalbumin (OVA)-induced allergic asthma.
Methods: C57BL/6 mice were sensitized to ovalbumin (OVA) by intraperitoneal injection with the adjuvant
aluminum hydroxide on days 0 and 7, and challenged with aerosolized OVA on days 14–16. In some cases, mice
were also exposed to 5 ppm acrolein vapor for 6 hrs/day on days 14–17. Lung tissues or brochoalveolar lavage
fluids (BALF) were collected either 6 hrs after a single initial OVA challenge and/or acrolein exposure on day 14 or
48 hrs after the last OVA challenge, on day 18. Inflammatory cells and Th1/Th2 cytokine levels were measured in
BALF, and lung tissue samples were collected for analysis of mucus and Th1/Th2 cytokine expression, determination
of protein alkylation, cellular thiol status and transcription factor activity.
Results: Exposure to acrolein following OVA challenge of OVA-sensitized mice resulted in markedly attenuated allergic
airway inflammation, demonstrated by decreased inflammatory cell infiltrates, mucus hyperplasia and Th2 cytokines.
Acrolein exposure rapidly depleted lung tissue glutathione (GSH) levels, and induced activation of the Nrf2 pathway,
indicated by accumulation of Nrf2, increased alkylation of Keap1, and induction of Nrf2-target genes such as HO-1.
Additionally, analysis of inflammatory signaling pathways showed suppressed activation of NF-κBa n dm a r g i n a l l y
reduced activation of JNK in acrolein-exposed lungs, associated with increased carbonylation of RelA and JNK.
Conclusion: Acrolein inhalation suppresses Th2-driven allergic inflammation in sensitized animals, due to direct protein
alkylation resulting in activation of Nrf2 and anti-inflammatory gene expression, and inhibition of NF-κB or JNK signaling.
Our findings help explain the paradoxical anti-inflammatory eff e c t so fc i g a r e t t es m o k ee x p o s u r ei na l l e r g i ca i r w a y sd i s e a s e .
Keywords: Cigarette smoke, Electrophile, Inflammation, Asthma, COPD, Nrf2, NF-κB, JNK
Background
Cigarette smoking remains prevalent worldwide, and is
among the main preventable causes of pulmonary and
cardiovascular disease and death. In addition to strong
links with lung cancer, cigarette smoking or exposure to
environmental tobacco smoke are also associated with
chronic pulmonary inflammatory diseases such as COPD
and asthma [1,2]. Strong associations exist between
cigarette smoking and the frequency and severity of se-
veral respiratory tract infections, such as influenza or tu-
berculosis, due to its impact on the immune system
[3,4]. Additionally, altered immune responses and local
oxidative stress within the airways of smokers may be re-
sponsible for increased incidence and persistence of re-
spiratory infections and chronic inflammation, which
ultimately contribute to the development and/or exacer-
bations of COPD and allergic airway inflammation [5-7].
Yet, the effects of tobacco smoke on the development
and severity of allergic asthma are not as clear. The
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asthma is relatively well established [8-10]. However, other
studies have failed to demonstrate an association between
smoking and asthma, and smokers were in some cases found
to be at lower risk of developing asthma compared to non-
smokers or ex-smokers [11,12]. Studies in animal models
confirm this dichotomy, and demonstrate that cigarette
smoke (CS) can promote allergic sensitization and exacer-
bate allergic responses [13-15], but can also attenuate allergic
inflammation and airway hyperresponsiveness during aller-
g e nc h a l l e n g eo fp r e v i o u s l ys ensitized animals [16-19].
Although the biological effects of CS are due to many
diverse mechanisms, several studies invoke the impor-
tant contribution of CS-derived reactive oxygen species,
primarily based on observations of protective effects of
thiol-based antioxidants [2,20,21]. However, the main
thiol-reactive agents within tobacco smoke are electro-
philic aldehydes and ketones, among which acrolein is
believed to be of primary importance [2,22-24]. Main-
stream CS contains levels of acrolein over 90 ppm [23],
and measurements of acrolein levels in airway secretions
or exhaled breath condensate from smokers suggest it
can reach 1–10 μM in the lung [25,26]. At doses ranging
from 0.2-6 ppm, the effects of acrolein vapor mimic
those of CS in inhalation studies [27-29]. Indeed, acro-
lein exposure exerts suppressive effects on the immune
system and inhibits alveolar macrophage responses and
function [29-31]. These anti-inflammatory and immuno-
suppressive effects of acrolein are thought to be due to
inhibition of redox-sensitive transcription factors, such
as nuclear factor-kappa B (NF-κB) and activator protein-1
(AP-1), through direct alkylation of proteins involved in
these pathways [32-36]. Furthermore, our recent studies
indicate that acrolein exposure alters alveolar macrophage
responses by suppressing classical “M1” macrophage re-
sponses and favoring alternative “M2” polarization pro-
grams, consistent with similar observations in smokers
[37]. Additionally, anti-inflammatory effects of various
alkylating agents, such as sulforaphane, curcumin and
15d-PGJ2, have been linked to alkylation of kelch-like
ECH-associated protein 1 (Keap1), and subsequent activa-
tion of the transcription factor Nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) (reviewed in [38]), which results in
the induction of a number of antioxidant and immuno-
suppressive genes, including heme oxygenase-1 (HO-1)
and glutamate-cysteine ligase (GCL), the rate limiting
enzyme in glutathione (GSH) synthesis [39].
Although epidemiological evidence suggests an associ-
ation between acrolein exposure and increased asthma
risk [40], limited reports have addressed the direct role of
acrolein in allergic airway inflammation [41]. The studies
presented herein were designed to explore the impact of
acrolein in a mouse model of allergic asthma. Our findings
indicate that acrolein exposure (5 ppm, 6 hrs/day) during
allergen challenge markedly attenuates Th2-driven inflam-
matory responses by inhibiting redox-sensitive inflamma-
tory signaling pathways including NF-κB and by activating
Nrf2 and inducing anti-inflammatory genes such as HO-1.
Methods
Animals and reagents
Male 6–8 week old C57BL/6 mice were purchased from
Charles River (Saint Constant, Quebec). All animal studies
were approved by the Institutional Animal Care and Use
Committee at the University of Vermont. All chemicals
were purchased from Sigma-Aldrich (St. Louis, MO) un-
less otherwise indicated.
Ovalbumin sensitization and challenge
Mice were injected intraperitoneally (i.p.) with 20 μgo f
ovalbumin (OVA) solubilized in sterile phosphate buffered
saline (PBS) in a 1:1 mixture with the adjuvant aluminum
hydroxide (Alum) (Imject® Alum; Thermo Scientific,
Rockford, IL) on days 0 and 7 to sensitize to OVA (OVA
group) (Figure 1). Sham-sensitized mice received PBS in
Alum (Sham group). All mice were exposed to aerosolized
1% OVA solution in sterile PBS for 30 min on days 14–16
and harvested either 6 hrs after the initial challenge on
day 14 or on day 18, 48 hrs after the last challenge.
Acrolein exposures
Mice were placed in a 2 L glass chamber situated in a
chemical fume hood and exposed to 5 ppm (11.5 mg/m
3)
of acrolein vapor for 6 hrs/day, on days 14–17 (Figure 1).
Vaporized acrolein was diluted with room air to 5 ppm
and passed through the chamber at 5 L/min. The acrolein
vapor concentration was continuously monitored using an
infrared sensor (Miran SapphIRe model M205, Thermo
Scientific, Franklin, MA). Control mice were exposed to
room air at 5 L/min for 6 hrs/day, on days 14–17.
Blood collection and OVA-specific IgG1 assay
Mice were sacrificed by i.p. injection of sodium pento-
barbital. Following euthanasia, blood was collected via
cardiac puncture into serum separator tubes, centrifuged
at 3,000 rpm for 10 min, and serum was kept frozen at
−80°C until analysis. An ELISA for OVA-specific IgG1
was performed as previously described [42].
BALF collection and BAL cell counts
After tracheal cannulation, lungs were lavaged 3 times
with 500 μL PBS, and lavage fluids were kept on ice until
processing. Lung lavage samples were centrifuged at
1500 rpm for 5 min at 4°C. The supernatant was frozen
in liquid N2 and the cell pellet was resuspended in
400 μL PBS containing 1% bovine serum albumin. Total
cell counts were performed using a hemacytometer, and
cytospins were prepared for differential cell counts by
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Hema 3, Fisher Diagnostics, Middletown, VA). At least
200 cells were counted per slide.
Airway epithelial cell protein extraction by lysis lavage
Selective removal of airway epithelial cell proteins was
performed as previously described [43] following a single
OVA challenge and acrolein exposure on day 14 (Figure 1).
Briefly, the trachea of each animal was cannulated, the alveo-
lar regions of the lung were blocked by infusion of low-
melting-temperature agarose followed by 1% dextrose, and
the excised lung was cooled to 4°C, in 5% dextrose for
10 min. The dextrose solution was then removed from the
lungs through simultaneous inversion and gentle suction
with a syringe, and was repeated until no more solution
could be recovered. The airways were then lavaged with
0.5 mL lysis buffer containing 2 M thiourea, 7 M urea, 4%
CHAPS, 1% Triton X-100 and 2% Protease Inhibitor Cock-
tail III (Calbiochem) to recover airway epithelial cell proteins.
Protein and RNA collection
Following either BALF collection or lysis lavage, lungs
were subsequently removed and two right lung lobes
were snap frozen in liquid N2 for biochemical analysis,
while one right lobe was placed in RNAlater (Ambion,
Austin, TX) for 24 hrs at 4°C before storage at −80°C for
subsequent RNA extraction.
Lung histology
The left lobe of the lungs was instilled with 4% paraformal-
dehyde in PBS for 10 min at a pressure of 25 cm H2Oa n d
placed into 4% paraformaldehyde overnight for fixation of
the tissue. Paraformaldehyde-fixed lung lobes were embed-
d e di np a r a f f i na n dc u ti n t o5μm thick sections. Sections of
paraffin-embedded lungs were deparaffinized and rehydra-
ted to water.
PAS staining and quantification
Tissue sections were stained for mucus using the Peri-
odic Acid-Schiff (PAS) method, and counterstained with
hematoxylin. For quantification of mucus metaplasia,
slides were scored using a scale of 0–4 (0 representing
no reactivity and 4 being the highest intensity staining
observed) for airway Periodic Acid-Schiff reactivity. Each
slide was scored by two blinded individuals. The inten-
sity was evaluated for each airway (at least 2) on each
section from each animal, and averaged.
H&E and immunofluorescence imaging
Left lung lobes were processed for hematoxylin and eosin
(H&E) staining. Immunofluorescence (IF) staining of lung
sections was performed with rabbit polyclonal anti-acrolein
(Abcam; 1:500), rabbit anti-serum Club Cell (Clara Cell)
Secretory Protein (CCSP; Millipore, Temecula, CA; 1:2000),
and secondary antibody goat anti-rabbit Alexa 555 fluo-
rescence conjugated IgG (Invitrogen; 1:500). For nuclear
staining, specimens were treated with 4,6-diamidino-2-
phenylindole (DAPI). Sections were evaluated by confocal
microscopy and analyzed using Metamorph imaging soft-
ware (v.7.8.2.0; Molecular Devices, Sunnyvale, CA). Repre-
sentative images of airways were selected for presentation.
Analysis of cytokine levels
The concentrations of IL-4, IL-13, TNFα, and IL-12p40
were measured in lung lavage supernatants using ELISA,
as recommended by the manufacturer (BD Biosciences,
San Diego, CA).
Quantitative reverse transcriptase polymerase chain
reaction (RT-PCR)
TRIzol (Invitrogen, Grand Island, NY) and a standard ex-
traction protocol (Qiagen, Germantown, MD) were used
to isolate total RNA from lung tissue. Total RNA was then
treated with DNase (Qiagen, Valencia, CA) to remove
contaminating DNA. Complementary DNA (cDNA) was
prepared from 1 μg of total RNA with MMLV reverse
transcriptase and Oligo(dT)15 primer (Invitrogen). Quan-
titative RT-PCR was performed using SYBR Green PCR
Supermix (Bio-Rad) and primers designed for various
mouse genes (Table 1). GAPDH expression was used as a
housekeeping gene and relative gene expression was calcu-
lated using the 2
-ΔΔCT method [44].
Day   0 18
Alum/OVA i.p.
(sensitization)
7 14   15  16   17
Alum/OVA i.p.
(sensitization)
OVA (1% aerosol challenge)
Acrolein (5 ppm)
Sacrifice
6 hrs after first 
OVA challenge
48 hrs after last
OVA challenge
Figure 1 Schematic diagram of experimental design. Mice were sensitized to OVA by intraperitoneal injection on day 0 and 7, with 20 μg
OVA and the adjuvent aluminum hydroxide (Alum). Sham-sensitized mice received PBS in Alum. Mice were challenged with an aerosolized 1%
OVA solution in sterile PBS for 30 min on days 14–16, immediately followed by exposure to acrolein (6 hrs; 5 ppm) on days 14–17. Mice were
sacrificed on either day 14 (immediately after acrolein exposure; 6 hrs) or on day 18 (48 hrs after the final OVA challenge).
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Nuclear extracts were prepared using the Nuclear Ex-
tract Kit (Active Motif, Carlsbad, CA) for analysis of
DNA binding activity of NF-κB or c-Jun with TransAM
NF-κB p65 and TransAM AP-1 c-Jun ELISA kits, re-
spectively (Active Motif, Carlsbad, CA).
Identification of acrolein-modified proteins by biotin
hydrazide labeling
Frozen lung tissues were homogenized in lysis buffer
(containing 50 mM HEPES, 250 mM NaCl, 10% glycerol,
1% Triton X-100, 1.5 mM MgCl2, 1 mM phenylmethyl-
sulfonyl fluoride, 1 mM EGTA, 2 mM Na3VO4,a n d
10 μg/mL of aprotinin and leupeptin) using a tissue
homogenizer (Biospec Products, Racine, WI). A total of
300 μg of protein was incubated for 2 hrs with constant
mixing with 100 μL of a 50 mM solution of biotin hydra-
zide (Pierce) (in dimethyl sulfoxide (DMSO), pH 6.0) in a
total volume of 200 μL. Samples were placed on ice and
incubated for 1 hr with 750 μLo f3 0m MN a C N B H 4 in
1X PBS. Biotin labeled samples were washed 6 times with
300 μL of 20 mM Tris/Cl pH 7.4 and concentrated to
100 μL in 3,000 MWCO filter devices (EMD Millipore,
Billerica, MA). To this 100 μL sample, 400 μLo fl y s i sb u f -
fer and 100 μL of High Capacity Neutravidin beads were
added and mixed constantly overnight at 4°C. The beads
were gently pelleted and washed 6 times with 1 mL 0.1 M
glycine, pH 2.8. Following a final wash with 1 mL of
20 mM Tris/Cl pH 7.4, samples were boiled for 5 min at
100°C in 100 μL of 2× reducing sample buffer (containing
0.125 M Tris/Cl, 4% SDS, 20% glycerol, 0.47 M β-
mercaptoethanol, 0.02% bromophenol blue, pH 6.8), and
immediately centrifuged at 14,000 rpm at 4°C for 5 min,
whereupon the supernatant containing the biotin-labeled
proteins was collected for analysis by Western blotting.
Analysis of protein thiol content by iodoacetamide-LC-biotin
labeling
Lysis lavage samples (100 μg protein) were washed 6x in
3000 MWCO centrifugation devices (Millipore) with
300 μL deoxygenated lysis buffer (50 mM Tris–HCl pH 7.4,
150 mM NaCl, 0.5% (vol/vol) Triton X-100 and 2% protease
inhibitor cocktail (Calbiochem)). Samples were concentrated
to 100 μL and then labeled with 100 μM (final concentra-
tion) iodoacetamide-LC-biotin (Pierce) in DMSO. Samples
w e r em i x e df o r1h ra tr o o mt e m pa n dt h e nm i x e d1 : 1w i t h
2× reducing sample buffer for Western blot analysis.
Western blot and cellular GSH analysis
Total lung homogenates, lysis lavage samples, or purified
biotin-labeled proteins were analyzed by SDS-PAGE and
Western blotting using antibodies against phosphorylated
(p) IκBα, p-cJun, cJun, JNK, IKKβ, Nrf2 (D1Z9C) XP®,
Keap1 (Cell Signaling, Danvers, MA), IκBα, RelA (Santa
Cruz Biotechnology, Santa Cruz, CA), HO-1 (BioVision,
Mountain View, CA; 1:1000), and β-actin (Sigma; 1:5000)
and detected using HRP-conjugated secondary antibodies
(Cell Signaling; 1:1000) or HRP-conjugated streptavidin
(Sigma; 1:20,000) and enhanced chemiluminescence
(Pierce). Lung homogenates were also used for analysis of
reduced GSH [45].
Statistical analysis
All experiments were performed 2–3 times (with 3–4
animals per treatment group). Data are expressed as
mean ± SEM and were analyzed by ANOVA with Tukey
correction for multiple comparisons. Results are consi-
dered statistically significant if p<0.05.
Results
Acrolein exposure suppresses allergen-induced
pulmonary leukocyte infiltration and mucus production
To explore the effects of acrolein inhalation on allergic air-
way inflammation, we used an ovalbumin (OVA) model of
asthma and exposed allergen-sensitized mice to acrolein
vapor during the OVA challenge phase, and evaluated air-
way inflammation 48 hrs after the final OVA challenge
(Figure 1). As expected, OVA challenge of sensitized mice
resulted in allergic inflammation, shown by increased num-
bers of primarily eosinophils, as well as neutrophils and lym-
phocytes in BAL fluids. Exposure to acrolein immediately
following allergen challenge significantly suppressed these
responses, shown by decreased total numbers of BAL cells
(Figure 2A), and decreased numbers of eosinophils, neutro-
phils and lymphocytes (Figure 2B), compared with animals
that were not exposed to acrolein. A trend towards suppres-
sion of allergen-induced pulmonary cell infiltration was also
observed immediately after a single exposure to acrolein fol-
lowing a single OVA challenge (Figure 2C and D), indicating
acrolein may have direct and immediate effects on inflam-
matory pathways. Additionally, acrolein exposure markedly
decreased allergen-induced mucus and goblet cell hyperpla-
sia as detected by PAS staining (Figure 3A and B), and
significantly decreased mRNA expression of the marker
genes Muc5ac and Gob5 (Figure 3C), 48 hrs after the
final OVA challenge.
Table 1 Primers used in the detection of cytokine
expression from mouse lung homogenates
Gene Sense (5′-3′) Antisense (5′-3′)
Muc5ac AGTCTCTCTCCGCTCCTCTCAAT CAGCCGAGAGGAGGGTTTGATCT
Il4 GGCATTTTGAACGAGGTCAC ATCGAAAAGCCCGAAAGAGT
Il13 AGGAGCTGAGCAACATCACA GTGGGCTACTTCGATTTTGG
Il12b ACGGCCAGAGAAAAACTGAA CTACCAAGGCACAGGGTCAT
Tnf TGGAAGACTCCTCCCAGGTA ACGGCATGGATCTCAAAGAC
Gclm ACCTGGCCTCCTGCTGTGTG GGTCGGTGAGCTGTGGGTGT
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expression and release after challenge
The reduced inflammation observed in antigen-challenged
mice that were exposed to acrolein suggests an inhibition of
pro-inflammatory cytokines responsible for inflammatory
cell recruitment and mucus production. To determine
whether acrolein exposure was affecting allergen-induced
cytokine production, RT-PCR analysis of cytokine gene ex-
pression was performed on lung tissues harvested from ani-
mals 6 hrs after a single OVA challenge and/or a single 6-hr
acrolein exposure (Table 2). As expected, OVA sensitization
and challenge increased lung tissue expression of several
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Figure 2 Acrolein exposure attenuates allergic airway inflammation in OVA-sensitized and challenged mice. C57BL/6 mice were
sensitized and exposed as shown in Figure 1. Bronchoalveolar lavage fluid (BALF) was collected on day 18 (A,B) or 14 (6 hrs after OVA challenge;
C,D) for enumeration of total cells (A, C) and differential cell counts (B,D). Results are expressed as mean ± SEM (n =3-10/group) (*, p<0.05).
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Figure 3 Acrolein exposure suppresses mucus/goblet cell hyperplasia in response to allergen challenge. Mucus/goblet cell hyperplasia
was evaluated 48 hrs after the last OVA challenge by PAS staining (A) which was scored and quantified (B). Lung tissue mRNA gene expression
of Muc5ac and Gob5 was analyzed by qRT-PCR (C). Results are expressed as mean ± SEM (n = 4/group) (*, p <0.05).
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uated following exposure to acrolein. OVA sensitization and
challenge also increased expression of Tnf (encoding TNFα),
but did not significantly affect Il12b (encoding IL-12p40). In
both cases acrolein exposure significantly suppressed mRNA
expression of these genes. Analysis of cytokine release into
the airway lumen of animals, 48 hrs after multiple OVA
challenge, demonstrated a trend towards increased release
of IL-4 and IL-13 in OVA-sensitized mice (Table 3), and
acrolein exposure did not significantly affect IL-4 or IL-13
release in these animals. However, OVA sensitization and
challenge resulted in a significant increase in IL-12p40 levels
in BAL fluid, which was significantly attenuated following
acrolein exposure (Table 3). Taken together, these results
indicate that acrolein is most likely affecting pathways re-
sponsible for the recruitment of inflammatory cells and the
mRNA expression and production of pro-inflammatory
cytokines in this model of allergic inflammation.
Acrolein attenuates IgG1 response to repeated OVA challenge
To ensure that animals were sensitized to OVA, IgG1
ELISA was performed on serum from animals 48 hrs after
the final OVA challenge (Figure 4A) or 6 hrs after the first
OVA challenge (Figure 4B). Indeed, all animals sensitized
to OVA produced OVA-specific immunoglobulin. An at-
tenuation of the IgG1 response was observed in acrolein
exposed animals 48 hrs after the final OVA challenge, but
this was not observed in animals that only received a
single OVA challenge and acrolein exposure.
Acrolein exposure results in epithelial cell acrolein-adduct
formation and disruption of thiol status
Our recent studies demonstrate that acrolein readily and
directly interacts with numerous proteins in lung cells
[37,46]. To confirm the adduction of inhaled acrolein to
airway epithelial cell proteins, IF detection of acrolein-
bound protein was performed on lung sections and quanti-
fied using Metamorph software. Figure 5A demonstrates
that acrolein exposure resulted in significantly increased
levels of acrolein-adducted protein in conducting air-
way epithelial cells compared to controls. Since acrolein
primarely reacts with cysteine residues [46], we analyzed
the protein cysteine thiol content of lung epithelial cells fol-
lowing acrolein exposure using iodoacetamide-LC-biotin
labeling. To this end, airway epithelial cell proteins were
obtained by lysis lavage, and labeled with iodoacetamide-
LC-biotin to determine thiol content. Successful isolation
of airway epithelial cells by lysis lavage was confirmed using
both H&E and IF staining of lung sections (Additional file
1: Figure S1). Figure 5B reveals that acrolein exposure leads
to a significant loss of epithelial cell protein thiol reactivity
compared to non-acrolein exposed controls. The main
mechanism of acrolein detoxification involves its conjuga-
tion to GSH, which can lead to disruption of cellular redox
homeostasis, especially after acute exposure to high con-
centrations. Indeed, while OVA exposure of sensitized mice
did not alter lung GSH status, acrolein exposure resulted in
reduced lung tissue GSH levels when measured directly
after acrolein exposure, especially in mice that were also
challenged with OVA (Figure 5C). No such changes in lung
tissue GSH were found 48 hrs after OVA and/or acrolein
exposures (results not shown), indicating that GSH deple-
tion by acrolein is transient, and is restored by induction of
GSH synthesis. Taken together, these results demonstrate
that acrolein exposure leads to formation of acrolein-
adducts and an acute loss of both protein and non-protein
thiols within airway epithelial cells.
Acrolein exposure activates the Nrf2 pathway
The transcription factor Nrf2 plays a key role in redox
homeostasis by regulating the activation of glutathione
synthesis and antioxidant defense genes, such as HO-1
[47]. To determine if Nrf2 was activated within the airway
epithelium following acrolein exposure, lysis lavage sam-
ples from animals exposed to a single OVA challenge and
acrolein exposure were analyzed for Nrf2-target protein
HO-1. Indeed, acrolein exposure resulted in significant in-
duction of HO-1 in airway epithelial cells (Figure 6A).
Nrf2 also transcriptionally regulates the catalytic (Gclc)
and regulatory (Gclm) subunits of glutamate-cysteine lig-
ase, the rate limiting enzyme in GSH synthesis [48] and
acrolein exposure was found to increase lung tissue
mRNA expression of Gclm and Gclc, reaching statistical
significance in acrolein-exposed OVA/OVA mice vs non-
Table 2 Effects of acrolein exposure on inflammatory
cytokine mRNA expression from mouse lung homogenates
6 hrs after OVA challenge
†
Gene Alum/OVA OVA/OVA Alum/OVA/ACR OVA/OVA/ACR
Il4 1.00±0.20 14.0±4.86
* 0.94±0.29
# 5.76±1.42
Il13 1.00±0.18 8.91±2.47
* 1.15±0.37
# 6.24±1.89
Il12b 1.00±0.17 1.28± 0.20 0.74±0.09
# 0.51±0.08
#
Tnf 1.00±0.15 2.46±0.23
* 0.87±0.13
# 1.00±0.15
#
†Cytokine levels were measured by RT-PCR of lung homogenates from animals
that were sensitized and challenged according to Figure 1. All values are
normalized to Alum/OVA controls (mean ± SEM; n = 6–9 mice/group) and
ANOVA was used to compare groups (
*, p <0.05 vs. Alum/OVA;
#, p< 0.05
vs OVA/OVA).
Table 3 Effect of acrolein on Th1/Th2 cytokine levels in
BAL fluids 48 hrs after OVA challenge
†
Alum/OVA OVA/OVA OVA/OVA/ACR
IL-4 33.5±9.3 68.6±27.0 61.6±10.5
IL-13 69.9±28.2 139.7±49.4 100.5±16.1
IL-12p40 60.5±7.7 600.4±66.9
* 194.0± 28.3
#
TNFα 146.3±41.6 96.1±20.1 191.6±47.6
†Cytokine levels were measured by ELISA of lung lavage fluids of animals that
were sensitized and challenged according to Figure 1. All values are expressed
as pg/mL (mean ± SEM; n = 5–10 mice/group) and ANOVA was used to
compare groups (
*, p< 0.05, vs. Alum/OVA;
#, p< 0.05, vs OVA/OVA).
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http://respiratory-research.com/content/14/1/107exposed OVA/OVA mice in case of Gclm (Figure 6B). We
next determined Nrf2 protein accumulation in whole lung
tissue lysates, as an indicator of Nrf2 activation, and ob-
served significant increases in Nrf2 in lungs from acrolein-
exposed mice, in both sham- and OVA-sensitized animals
(Figure 6C). Consistent with the observed accumulation
and apparent activation of Nrf2, we observed increased
carbonylation of Keap1 in lung homogenates following
acrolein exposure as detected by biotin hydrazide labeling
and Western blot analysis (Figure 6C), indicating direct al-
kylation of Keap1 by acrolein through Michael addition to
its cysteine residues [49]. Interestingly, the extent of
acrolein-induced Nrf2 accumulation and Keap1 alkylation
appeared to be reduced in OVA-sensitized and challenged
mice compared to sham-sensitized mice, although this did
not reach statistical significance. Together, these results in-
dicate that acrolein exposure results in alkylation of Keap1
and thereby leads to activation of the Nrf2 pathway in air-
way epithelial cells, resulting in increased expression of
antioxidant and anti-inflammatory genes, which could
contribute to the inhibitory effects of acrolein on OVA-
induced allergic inflammation.
Acrolein exposure inhibits allergen-induced activation of
the NF-κB pathway
OVA-induced inflammation requires the activation of the
NF-κB and c-Jun N-terminal kinase (JNK)/AP-1 pathways,
and both pathways were previously shown to be affected
by components of cigarette smoke [34,37,50]. Analysis of
phosphorylation of IκBα, the inhibitor of NF-κB, indicated
significantly increased NF-κB activation following OVA
sensitization and challenge, and this was significantly at-
tenuated following acrolein exposure (Figure 7A). Using
DNA-binding activity assays on nuclear extracts from lung
tissues, we evaluated the activation of NF-κB 6 hrs after a
single OVA challenge with or without acrolein exposure.
As shown, although OVA challenge did not significantly
enhance overall NF-κB activation, acrolein exposure
inhibited NF-κB binding activity in both sensitized and
sham mice (Figure 7B), demonstrating the ability of acro-
lein to inhibit NF-κB signaling. Activation of JNK signaling
was evaluated by analysis of phosphorylation of c-Jun.
Although OVA challenge did not significantly increase
c-Jun phosphorylation above control levels, acrolein
exposure tended to inhibit c-Jun phosphorylation in OVA-
challenged mice (Figure 7C). Similarly, while OVA chal-
lenge did not significantly increase overall c-Jun nuclear
DNA-binding activity, acrolein exposure tended to reduce
its activity (Figure 7D). Collectively, these findings indicate
that OVA challenge is associated with activation of NF-κB
and perhaps JNK, and that acrolein exposure inhibits
the NF-κB pathway, and also appears to inhibit the JNK
pathway.
Acrolein adduction of proteins within the NF-κB and JNK
pathways
Previous findings indicate that acrolein can inhibit NF-
κB and JNK signaling by direct alkylation of critical pro-
teins associated with these pathways [33-35,37,51]. To
address this possibility, we evaluated acrolein-induced
protein carbonylation by Michael addition in lung ho-
mogenates of animals subjected to a single OVA chal-
lenge and/or acrolein exposure, using biotin hydrazide
labeling and avidin purification of biotinylated proteins
[52]. Indeed, acrolein exposure significantly increased
detectable biotinylation within the NF-κB protein RelA in
lungs of OVA-sensitized and challenged mice (Figure 8A),
which may explain the decreased DNA binding activity
observed in Figure 7B. Since acrolein exposure was
found to inhibit OVA-induced phosphorylation of IκBα
(Figure 7A), we also determined whether acrolein ex-
posure led to modification of IκBk i n a s eb e t a( I K K β),
t h ee n z y m er e s p o n s i b l ef o rI κBα phosphorylation. Acro-
lein exposure indeed led to significantly increased levels
of biotin hydrazide-labeled IKKβ in lungs of OVA-
sensitized and challenged mice, indicating direct alky-
lation of this protein (Figure 8B). Similarly, as shown in
Figure 8C, increased amounts of biotin-labeled JNK
AB
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Figure 4 Acrolein exposure does not directly inhibit OVA-specific serum IgG1 production. Serum IgG1 was determined by ELISA on day 18
(48 hrs after final OVA challenge; A) or day 14 (6 hrs after initial OVA challenge; B). Results are expressed as mean ± SEM (n =4-6/group) (*, p <0.05).
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http://respiratory-research.com/content/14/1/107isoforms were detected in lung homogenates of animals
that were exposed to both OVA and acrolein, which we
recently associated with inhibition of JNK signaling [37].
Collectively, these findings suggest that the inhibitory
effects of acrolein on the NF-κBa n dJ N Kp a t h w a y sa r ea t
least partly due to direct modification by Michael addition
of critical proteins within these pathways.
Discussion
It is well documented that tobacco smoke exposure can
contribute to the development of allergic asthma [5,53],
and can worsen asthma symptoms and enhance cortico-
steroid resistance [54,55]. However, a number of studies
have also shown that smoke exposure suppresses some
mediators of allergic inflammation such as eosinophilia
[16,17]. The biochemical mechanisms by which cigarette
smoking contributes to lung disease are highly complex,
but various lines of evidence support an important role
of reactive aldehydes, such as acrolein, found within
cigarette smoke [40,56]. Indeed, acrolein exposure in ro-
dent models can induce airways hyperresponsiveness [57]
or mucus metaplasia [58,59], important hallmarks of
asthma. In addition, based on previous studies demonstra-
ting that acrolein exposure can suppress innate Th1-driven
immune responses [36,37,51], we speculated that such ac-
tions may promote Th2-polarized inflammatory responses
during allergic inflammation. However, our present results
indicate that acrolein exposure of allergen-sensitized mice
immediately after allergen challenge significantly inhibits
overall allergic airway inflammation, cytokine responses,
and mucus metaplasia. Our findings are also consistent
with a number of studies showing that exposure of OVA-
sensitized mice to CS both during and after OVA challenge
suppresses eosinophilic inflammation and Th2 cytokine
responses [16,60], and imply that these anti-inflammatory
effects of CS may in part be due to acrolein.
Acrolein exposure was found to suppress both Th1 cy-
tokines (e.g. IL-12p40) and Th2 responses in the present
(See figure on previous page.)
Figure 5 Acrolein exposure induces protein-adduct formation and disruption of thiol status within the epithelium. (A) Lung sections
were obtained 6 hrs after a single OVA challenge and acrolein exposure (day 14) and probed with anti-acrolein antibody (red) or DAPI (blue), and
staining intensity was quantified using Metamorph software A control image without primary antibody (no 1º) is shown to demonstrate
specificity. (B) Epithelial proteins collected by lysis lavage were labeled with the cysteine-reactive probe Iodoacetyl-LC-biotin, and biotin labeling
was visualized by streptavidin blot and quantified using Image J software. (C) Reduced GSH was measured by HPLC in lung tissue homogenates.
Results are expressed as mean ± SEM (n =3-6/group) (*, p <0.05).
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Figure 6 Acrolein exposure activates the Nrf2 pathway. Lung tissue homogenates or lysis lavage samples were collected 6 hrs after a single
OVA challenge and/or acrolein exposure. (A) Analysis of HO-1 protein levels in lysis lavage samples by Western blot. (B) PCR analysis of Gclm and
Gclc in lung tissues. (C) Evaluation of biotin hydrazide-labeled proteins and whole lung lysates for the Nrf2 repressor Keap1. Band densities were
quantified using Image J software. Results are expressed as mean ± SEM (n =3-6/group) (*, p < 0.05).
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http://respiratory-research.com/content/14/1/107studies. Therefore, the observed suppression of allergic
inflammation and mucus metaplasia were not due to
Th2 suppression by activation of Th1 responses, but ra-
ther to its more general anti-inflammatory properties.
Since the cytokine analysis was performed on BAL
fluids, measured cytokines most likely originated prima-
rily from alveolar macrophages, extravasated immune
cells, and dendritic cells. Indeed, since dendritic cells
may be a major source of IL-12p40, its reduction may
reflect inhibited dendritic cell responses. Similarly, the
suppressive effects on allergic inflammation may also be
related to the ability of acrolein to inhibit Tcell responses
and proliferation [31].
Because of its strong chemical reactivity, our studies
were focused on acute mechanisms by which acrolein af-
fects critical processes involved in regulating airway inflam-
mation. First, acrolein can stimulate anti-inflammatory
responses by activating the Nrf2 pathway through direct
interaction with redox-sensing cysteine residues within its
inhibitor Keap1 [49]. Accordingly, our findings of increased
alkylation of Keap1, accumulation of Nrf2 protein, and in-
duction of the Nrf2-regulated genes HO-1 and GCL, in-
deed indicate the involvement of Nrf2 activation in
response to acrolein exposure, and suggest that acrolein ac-
tivates this pathway by direct modification of Keap1. How-
ever, acrolein may also activate Nrf2 by activating kinase
signaling pathways to promote phosphorylation of Nrf2,
critical for its migration into the nucleus and transcrip-
tional activity [39]. The importance of Nrf2 in allergic
inflammation has been addressed in studies with Nrf2-
deficient mice, which show enhanced inflammation and
airway hyperresponsiveness in a similar OVA model of aller-
gic asthma [61]. Additionally, Nrf2-deficient mice were also
found to be more vulnerable to the oxidative and inflamma-
tory effects of chronic cigarette smoke exposure [62]. Vari-
ous reports indicate that severity of asthma or COPD is
associated with impaired Nrf2 activation and function, due
to chronic oxidative stress or post-translational modification
of Nrf2 [63-65], and chemical activators of Nrf2, such as
food-derived electrophilic compounds (e.g. sulforaphane,
curcumin), are thought to have therapeutic benefit [39]. Our
studies would suggest that acrolein might similarly suppress
allergic inflammation, since it has anti-inflammatory proper-
ties similar to other electrophiles [37]. However, its chemical
reactivity differs from many other anti-inflammatory
electrophiles which may be responsible for its toxic pro-
perties or ability to promote inflammation or airways
hyperresponsiveness [41,66]. Also, while acute exposure to
cigarette smoke or acrolein might suppress inflammation
due to Nrf2 activation, this may not apply to more chronic
conditions in which the defensive capabilities of the Nrf2
pathway may be impaired.
Various lines of evidence indicate the importance of
epithelial NF-κB in allergic airway inflammation, chemo-
kine/cytokine-production and mucus metaplasia in aller-
gic inflammation [67,68], and a number of previous
findings indicate that acrolein can suppress NF-κB sig-
naling due to modification of redox-sensitive cysteine
residues within this pathway [33,34,36]. Indeed, our
present results indicate that acrolein exposure inhibits
OVA-induced IκBα phosphorylation and nuclear trans-
location of RelA, and we obtained direct evidence that
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Figure 7 Inhibition of NF-κB and JNK signaling pathways by acrolein exposure. Lung tissue homogenates, collected 6 hrs after a single
OVA challenge and/or acrolein exposure, were evaluated for phosphorylation of IκBα (A), DNA binding activity of the RelA subunit of NF-κB (B),
phosphorylation of c-Jun (C) or c-Jun DNA-binding activity (D). Blots were quantified using Image J software, and results are expressed
as mean± SEM (n= 3-9/group) (*, p<0.05).
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http://respiratory-research.com/content/14/1/107acrolein exposure led to increased carbonylation of both
RelA and IKKβ, suggesting their direct alkylation by
acrolein, which is in accordance with previous studies
[34,35,37,51]. Thus, acrolein exposure appears to sup-
press NF-κB signaling both at the level of IKKβ, a critical
redox-sensitive kinase within the NF-κB activation path-
way [69], and at the level of RelA to inhibit its DNA
binding activity [34].
Allergic inflammation may also involve activation of
JNK [70] and AP-1 transcription factor family members,
which regulate the expression of genes involved in a
number of cellular functions including inflammation and
pulmonary defense [71]. We previously demonstrated
that acrolein can form adducts with specific cysteines
within JNK2, which may play a prominent role in the
immunosuppressive effects of acrolein [37]. Our present
studies indicate that acrolein exposure increased alky-
lation of JNK isoforms, which was associated with appa-
rent suppression of OVA-induced c-Jun phosphorylation
and c-Jun DNA binding activity.
Taken together, our findings indicate that acrolein can
suppress allergic airway inflammation by activating Nrf2
and inhibiting major inflammatory signaling pathways
related to direct alkylation of critical redox-sensitive pro-
teins in these pathways. It is important to emphasize
that acrolein exposure does not suppress inflammation
by a single specific mechanism, but by a combination of
protein modifications that collectively result in anti-
inflammatory responses, due to activation of Nrf2 as
well as inhibition of NF-κB and JNK signaling. This
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Figure 8 Acrolein adduction of proteins involved in NF-κB and JNK signaling. Lung tissue homogenates, collected 6 hrs after a single OVA
challenge and/or acrolein exposure, were analyzed for carbonylated proteins by biotin hydrazide labeling and avidin purification. Purified
biotinylated proteins were evaluated by Western blot for RelA (A), IKKβ (B) or JNK (C). Representative blots are shown. Band intensities were
quantified using Image J and expressed as mean±SEM (n=6/group) (*, p< 0.05).
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http://respiratory-research.com/content/14/1/107property is not unique to acrolein but is shared by many
biologically relevant anti-inflammatory electrophiles, in-
cluding suggested Nrf2 activators such as sulforaphane,
that can also inhibit NF-κB and JNK signaling through
direct modification of redox-sensitive cysteines [37]. In
addition to these direct anti-inflammatory actions, acro-
lein exposure may also impact on allergic inflammation by
more indirect systemic actions, such as the release of
stress hormones such a corticosterone [72]. Although
these anti-inflammatory actions of acrolein might be
interpreted as protective in the context of inflammatory
diseases such as asthma, it is prudent to point out that
acrolein is reactive with a broader spectrum of biological
targets compared to other anti-inflammatory electrophiles
[66], and these alternative actions may be responsible
for its significant toxic properties and adverse health effects
and ability to induce airways hyperresponsiveness.
Conclusions
In summary, our studies indicate that acrolein may ac-
count for the reported anti-inflammatory effects of
cigarette smoke in allergic asthma, and highlight multiple
and diverse mechanisms by which acrolein exerts such
anti-inflammatory actions, through inhibition of NF-κB
and JNK pathways and activation of Nrf2 and subsequent
anti-inflammatory gene induction. We believe that our
findings are mostly relevant in the context of active smok-
ing, which has sometimes been associated with improved
asthma symptoms, and may in fact help explain the bene-
ficial actions of the past use of “asthma cigarettes” in
treating asthma symptoms (e.g. [73]). Moreover, our fin-
dings are also important in helping understand the alter-
ations in inflammatory/immune processes within smokers
with asthma, which may for a large part be due to the ac-
tions of acrolein. Future studies using acrolein-specific
antibodies as a diagnostic tool will be instrumental in ad-
dressing the importance of acrolein in CS-related respira-
tory diseases, and may help assess the importance of
acrolein-metabolizing enzymes, such as GSH S-transferase
P1 [74], in asthma development or severity.
Additional file
Additional file 1: Figure S1. Isolation of airway epithelial cells by lysis
lavage. Epithelial cells were selectively removed using the lysis lavage
technique. Untreated lungs (A and C) and lungs having undergone
lysis lavage (B and D) were stained with H and E (A and B) or
immunofluorescence (C and D) for Club Cell (Clara Cell) Secretory
Protein (CCSP) (red) and DAPI (blue).
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